GLP-1 Therapy and Kidney Disease: The FLOW Trial and Beyond

The FLOW trial, published in The New England Journal of Medicine in 2024, demonstrated that semaglutide significantly reduces the progression of kidney disease in patients with type 2 diabetes and chronic kidney disease (CKD). This finding adds a major new dimension to the clinical rationale for GLP-1 therapy.

FLOW (Evaluate Renal Function with Semaglutide Once Weekly) enrolled 3,533 patients with type 2 diabetes and CKD (eGFR 50–75 mL/min/1.73m² with albuminuria, or eGFR 25–50 mL/min/1.73m²). Patients were randomized to semaglutide 1.0 mg weekly or placebo.

The primary endpoint was a composite of:

• Kidney failure (dialysis, transplant, or eGFR <15)
• ≥50% reduction in eGFR
• Death from kidney or cardiovascular causes

The trial was stopped early due to overwhelming efficacy:

• Primary endpoint: 24% reduction with semaglutide (HR 0.76, 95% CI 0.66–0.88)
• Kidney failure: 23% reduction
• eGFR decline: Significantly slower in semaglutide group
• Cardiovascular death: 29% reduction
• All-cause mortality: 20% reduction

The FLOW trial established semaglutide as a kidney-protective agent in patients with T2D and CKD — a population with very high risk of kidney failure and cardiovascular death. The FDA approved semaglutide for reducing kidney disease progression in T2D patients with CKD based on this data.

The mechanisms by which GLP-1 agonists protect the kidney are not fully understood, but several have been proposed:

Hemodynamic effects: GLP-1 agonists reduce intraglomerular pressure by dilating the afferent arteriole and constricting the efferent arteriole — similar to the mechanism of ACE inhibitors and ARBs.

Anti-inflammatory effects: GLP-1 agonists reduce renal inflammation, which is a key driver of CKD progression.

Anti-fibrotic effects: GLP-1 agonists may reduce renal fibrosis, which is the final common pathway of CKD progression.

Metabolic effects: Weight loss, improved glycemic control, and reduced blood pressure all contribute to renal protection.

Most GLP-1 agonists do not require dose adjustment for CKD:

• Semaglutide: No dose adjustment required for any stage of CKD
• Tirzepatide: No dose adjustment required for mild to moderate CKD; limited data for severe CKD
• Liraglutide: No dose adjustment required; use with caution in severe CKD

For patients with CKD on GLP-1 therapy:

• Monitor eGFR and urine albumin-to-creatinine ratio (UACR) every 3–6 months
• Monitor for volume depletion (GI side effects can cause dehydration, which is particularly dangerous in CKD patients)
• Monitor potassium (GLP-1 agonists can affect potassium levels)

Patients with CKD are often on multiple medications. Key interactions to consider:

• Metformin: Hold if eGFR <30; monitor closely if eGFR 30–45
• SGLT2 inhibitors: Reduced efficacy at lower eGFR; check current guidelines for specific thresholds
• Renally-cleared medications: Monitor levels if GI side effects cause dehydration

The combination of GLP-1 agonists and SGLT2 inhibitors provides complementary renal protection:

• GLP-1 agonists: Hemodynamic, anti-inflammatory, and metabolic protection
• SGLT2 inhibitors: Hemodynamic protection (reduced intraglomerular pressure) and direct tubular effects

Current guidelines recommend this combination for patients with T2D and CKD who can tolerate both agents.

Patients presenting for GLP-1 weight management therapy should be screened for CKD:

• eGFR (from basic metabolic panel)
• UACR (spot urine albumin-to-creatinine ratio)

Identifying CKD strengthens the clinical rationale for GLP-1 therapy and may support insurance coverage.

Document the CKD indication in the medical record. The FLOW trial data provides a strong evidence base for GLP-1 prescribing in patients with T2D and CKD.

Request portal access →

This content is for informational and educational purposes only. It does not constitute medical advice. Prescribers should review current prescribing information and use clinical judgment.